BofA Securities Maintains AbbVie(ABBV.US) With Hold Rating, Announces Target Price $191
AbbVie (ABBV.US) JAK inhibitor "upadacitinib" is proposed for priority review in China.
On December 10, the official website of the Center for Drug Evaluation (CDE) of China's National Medical Products Administration announced that AbbVie (ABBV.US) has applied for the inclusion of upadacitinib sustained-release tablets in priority review, with the intended indication being the treatment of adult giant cell arteritis (GCA).
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
AbbVie Treatment of Multiple Myeloma Granted FDA Orphan Designation
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
